Malignant cells

Malignant cells is a general term referring to cells that have undergone malignant transformation, acquiring the ability to grow uncontrollably, invade surrounding tissues, and potentially metastasize to distant sites. These are the fundamental units of all cancers. Malignant transformation involves genetic and epigenetic changes that disrupt normal cellular processes such as cell cycle regulation, apoptosis, DNA repair, and signal transduction pathways. As a result, malignant cells exhibit hallmark behaviors including sustained proliferative signaling, resistance to cell death, evasion of growth suppressors, replicative immortality, induction of angiogenesis, activation of invasion and metastasis programs, metabolic reprogramming, and immune system evasion. Is there something wrong with this target? Yes—“malignant cells” is not a specific molecular target but rather a broad category describing any cancerous cell regardless of tissue origin or molecular subtype. In drug development or pharmacology databases focused on therapeutic targets (such as receptors or enzymes), "malignant cells" would be considered too generic for structured annotation as a single actionable target. Further notes: While many drugs are designed to kill or inhibit malignant/cancerous/tumor/neoplastic cells in general—such as chemotherapies—they do not act on "malignant cell" as an individual molecule or receptor but rather on specific proteins/pathways within these populations. Targeted therapies focus on defined molecules like EGFR receptor tyrosine kinase in lung cancer or HER2 in breast cancer; these are valid canonical targets with clear molecular identities. Biomarkers for patient selection also refer to specific gene mutations/proteins expressed by subsets of malignant cells—not “malignant cell” itself. In summary: “Malignant cell” is not an appropriate entry for structured therapeutic target information because it lacks specificity; it refers broadly to any cancerous cell type rather than a discrete molecule amenable to direct targeting by drugs. If you need information about specific molecular targets commonly found in malignant/cancerous/tumor/neoplastic cells—such as EGFR receptor tyrosine kinase (“Epidermal growth factor receptor”), BRAF V600E mutant protein (“B-Raf proto-oncogene serine/threonine-protein kinase V600E”), etc.—please specify the particular protein/gene/receptor/enzyme/pathway involved.

Other names

Cancer cellsTumor cellsNeoplastic cellsMalignant tumor cells